"iXCells Biotechnologies Launches iPSCore™ Platform for Generating Highly Characterized iPSC-derived Human Cell Models
• This modular system is designed to streamline the development of highly characterised human cell models derived from induced pluripotent stem cells (iPSCs).
• The iPSCore™ platform integrates advanced tools, technical expertise and industry experience to develop iPSC-derived products using ethically sourced biospecimens, including cell fractions such as PBMCs or fibroblasts from both healthy individuals and patients.
• These cells can be reprogrammed, genetically modified, and differentiated into a wide range of cell types and 3D models, tailored to specific research or therapeutic needs.
iPSCore™ Enhances Precision in Cell Characterization & Production
• Strong focus on descriptive & functional characterization, enabling broad application in downstream assays.
• Processes over 1,000 samples annually, with an impressive 96% success rate.
• Projected output growth by 2026, especially in patient-derived cell production.
Platform siginificance
• The platform places strong emphasis on both descriptive and functional characterisation, enabling its use in a variety of downstream assays.
• Currently, iPSCore™ processes over 1,000 samples each year, achieving a success rate of more than 96%.
• Output is expected to significantly increase by 2026, particularly in patient-derived cell production.
For the demand on relevant human cell models
• iXCells developed this platform in response to the growing demand for relevant human cell models, which are often not readily available and require time-consuming design and engineering.
• The system supports the creation of both standard and customised cell products, with options for off-the-shelf or made-to-order availability.
iXCells Advances iPSC Technology for Drug Development
• Pharmaceutical & biotech sectors are shifting towards alternatives to animal models.
• The FDA Modernization Act 2.0 supports non-animal drug safety & efficacy evaluation.
• iPSC-derived models are proving to be more predictive and reliable, addressing unmet medical needs.
• iPSCore™ launch showcases iXCells' commitment to harnessing iPSC technology for advanced research.
• Combines cell reprogramming, editing & differentiation to replicate human biology in vitro.
Lays the groundwork for future innovations:
• In vitro drug screening across diverse human genotypes.
• AI-powered disease pattern identification.
Moving towards ""clinical trials on a plate"".